Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacul… (NCT01291121) | Clinical Trial Compass
CompletedNot Applicable
Intravitreal Ranibizumab in Exudative Age-related Macular Degeneration With Posterior Vitreomacular Adhesion
South Korea30 participantsStarted 2011-02
Plain-language summary
The main objective is to determine the efficacy of intravitreal administration of Ranibizumab combined with intravitreous injection of expansile gas and induction of posterior vitreous detachment on best-corrected visual acuity and ocular coherence tomography (OCT) macular thickness in subjects with neovascular age-related macular degeneration (AMD) with posterior vitreomacular adhesion (VMA).
Secondary objectives are to assess the safety and tolerability of the intravitreal administration of Ranibizumab combined with intravitreous injection of expansile gas.
Who can participate
Age range50 Years
SexALL
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Age \> 50 years old
✓. Exudative AMD proven by fundus photograph and fluorescein angiography (FA)with VMA proven by OCT
✓. Ability to provide written informed consent and comply with study assessments
Exclusion criteria
✕. Previous anti-VEGF treatment
✕. More than three prior treatment with PDT
✕. Previous subfoveal focal laser photocoagulation in the study eye
✕. Laser photocoagulation (juxtafoveal or extrafoveal) in the study eye within 1 month preceding day 0
✕. Subfoveal fibrosis or atrophy in the study eye
✕. History of vitrectomy surgery in the study eye
✕. Significant concurrent ocular or macular diseases in the study eye
✕
What they're measuring
1
Changes from baseline in visual acuity and central macular thickness at 12 months